CSF2 and myeloid sarcoma: For example, when MS was treated with Rituximab depleted CD20+ cells, colony stimulating factor (CSF) and serum B cells were greatly decreased, leading to low clinical recurrence, reduced intracranial inflammation and better curative effect [4] .